Seeking Alpha

Deutsche, Needham talk eteplirsen as Sarepta falls by nearly two-thirds

  • Deutsche's Robyn Karnauskas weighs in on what, quite frankly, has been a nightmarish day for Sarepta Therapeutics (SRPT -63.4%).
  • Karnauskas is now modeling a 2016 launch for eteplirsen. "Every 1 year delay impacts the DCF by $10/share," the analyst notes.
  • Needham's Chad Messer is also out with some commentary, saying that while he "continues to believe in the efficacy and safety of eteplirsen, [he is] downgrading [the] shares to Hold [after losing] visibility to the regulatory hurdles for approval."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector